Bodisen Biotech Share Discussion Threads

[pictureframe] 20/3/2007 10:02

dead duck imho.....to many unanswered question. Yanks will murder this when market opens

[influence] 16/2/2007 08:15

closed last night at $4.35

[influence] 13/2/2007 17:54

Flying in USA at the moment. $4.40

[influence] 12/2/2007 21:53

interesting trades after hours.

[influence] 12/2/2007 19:55

historically these class action do not normally have much effect on the share price in the long term. Trouble in this case is that there is other uncertaintly.

The Amex problem should be resolved in 6/7 weeks and final results should be out in 5 weeks time.

Fundementals are ok. Company is debt free and cash positive and the shares look very cheap. They even have a near 9% holding in China Gas.

Not a share for me but I am following this with interest.

[leighbarton] 12/2/2007 17:08

Curious, win plaudits and yet share is really being hammered in the US at the moment despite imminent lifting of AMEX sanction. Are the shareholder actions really a big concern?

[cimbom] 12/2/2007 15:49

Ms. Qiong Wang, Director and Former CEO of Bodisen, Won the Award of 'China Pioneering Talent of 2006'

PrintE-mailDisable live quotesRSSDigg itDel.icio.us

Last Update: 12:08 PM ET Feb 8, 2007


SHAANXI, China, Feb 8, 2007 (PrimeNewswire via COMTEX) -- Bodisen Biotech, Inc. (BBC : bodisen biotech inc com
News , chart, profile, more
Last: 4.24-0.06-1.40%

10:28am 02/12/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
BBC4.24, -0.06, -1.4%) (London:BOD) (website: today announced that Ms. Qiong Wang, director and former CEO, won the award of "China Pioneering Talent of 2006."
The grand opening of "China's Top Ten Series Talents of 2006" was jointly hosted on February 4, 2007 by the Educational, Scientific, Cultural, Healthcare and Sports Committee of the National Chinese People's Political Consultative Commission, the U.N. Educational, Scientific, and Cultural Organization (UNESCO), The China National Chamber of Industry & Commerce, The Association of China's International Friendship, etc. Deputy Commissioners of the China National People's Congress, Xu Jialu, and Wuyunqimuge, Vice Chairpersons of China National Political Consultative Committee, Mr. Sun Fulin, Mr. Abulaiti Abudurexiti, Mr. Zhou Tienong, and former defense minister, Mr Chi Haotian attended the ceremony and delivered awards to the winners. Ms. Qiong Wang, director and former CEO of Bodisen Biotech Inc. earned the award of "Pioneering Talent."
The criteria for the "China's Top Ten Series Talents" were "innovation, perfection, model," advocating the principles of people as the ultimate purpose for reforms, developments, and renaissance. The board of review consists of officials, experts, media reps, and masses reps. The goal is to select the best candidates from different industries representing the greatest potential in China. This is a widely watched national honor, which is in its second annual round. The ten series of talents refer to innovation, talents, commerce, integrity, education, science & technology, management, construction, and charisma. Each series will see ten winners so that in total we have 100 winners from all over China here.
Bodisen Biotech Inc. achieved great success in a few years under the leadership of Ms Qiong Wang.
Qiong Wang is the only entrepreneur from Shaanxi to earn this honor, which is her second national honor in The Great People's Congress Hall after her award of "China Pioneering Personality."
About Bodisen Biotech, Inc.
Bodisen Biotech Inc. is a leading manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw materials certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. Ranked the 16th fastest growing company in China by Forbes China in January 2006, the Company is headquartered in Shaanxi province and is a Delaware corporation. The Company's environmentally friendly "green" products have been proven to improve soil and plant quality, and increase crop yields.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Bodisen Biotech Inc.
Bodisen Biotech, Inc.
Investor Relations:
Hong Zhu
[phone]
[e-mail]

[influence] 10/2/2007 08:55

anymore thoughts on this company?

[vish65] 16/1/2007 20:53

Yes it is - but i hardly look now as i'm exhausted with this stock .Hopefully Amex resolution may give a little lift but it just too painfull to look at now . Better thngs happening elsewhere

[leighbarton] 16/1/2007 20:05

Is it just me or does the UK pricing seem completely out of sync with the US? There must be arbitrage opportunities here.

[thecleaner] 15/1/2007 20:41

As the board are a load of liars best to sell up until the situaton clears. I am not a holder though

[leighbarton] 12/1/2007 15:08

Bonzo, good analysis. I think there is a chance of recovery to 500p, but alot rides on no more surprises on the downside. Unfortunately history suggests that when a company starts on the road of negative news it tends to continue for some time. I would not be surprised at at least one more bad news story. The results are key - and behind that what happens to cashflow and bad debt.

History also suggests that the market is very slow to forgive, therefore even if the company delivers stellar results it will take a few before the company inches back into favour. I think we are in for a long ride but at the moment I am prepared to hold.

[cimbom] 10/1/2007 11:14

Did anyone catch this mention by Forbes?



Bodisen Biotech (amex: BBC - news - people ) said it anticipates a 74% jump in 2006 earnings, sending its shares up in morning trading.

[bonzophil] 08/1/2007 20:20

Year Quarter Net Rev/$m Net income/$m Eps/Cents
2005 1 4.4 1.21 .05
2 8.4 2.69 .18
3 10.5 2.87 .19
4 7.4 2.03 .06
Total 31.0 8.80 .48

2006 1 8.5 2.2 .16
2 16.4 5.9 .32
3 12.7 3.2 .18
4 5.4 1.6 .05 Estimate
Total 43.0 12.9 .71

The above figures are what I have pieced together from all the quarterly accounts and the latest trading statement.
Overall the year on year improvement in eps is estimated at 48% which is less than originally estimated by the company, but still good. Total revenue was $43m which was exactly the amount stated as forward orders in the Nov 2005 trade show figures, which they stated was likely to be 70% of the total revenue for 2006??

Estimates for 2007 were stated in early 2006 to likely be double with the opening of the factories in the NE and NW of the country.
This is obviously not going to happen as the NW factory will not open until at least the 3rd Q 2007, and the NE factory has disappeared off the radar.
One hopes that the drop in 4th Q figures is due to the 1 month shutdown, and will prepare them for full throughput for 2007.

I think the best we can hope for in 2007 is a 20% increase in sales and eps.
Also in there is the stake in China Natural Gas valued at about $6m

The price earning for this year is about 7, and now that Wang has gone confidence may start to return. 2008 earnings could double from this years figure. I would expect the share price to recover to around the 5-600 level this year, so I think I'll hang on to my losses at present.

[leighbarton] 08/1/2007 16:58

I agree this is a real mixed bag, but not all bad news. The issue is less what Herb makes of it (and sadly he has got parts of this right - even if with a large dose of unacceptable xenophobia), but rather the US lawyers that are circling like vultures.

The results aren't bad:

Sales $43m vs £31m
Net Income $12.9m vs $7.4m

$43.8m sales signed up for 2007 from the 2 trade shows (not sure how this compares with expectations). Not sure where you get insufficient capacity from: the statement says these orders can be met from the Yanling factory.

Supply from Xinjiang factory should provide sales over and above what has been reported as will be supplying locally to a market that previously had been expensive for them to service. However this now is not coming on stream until 4 Q 2007

Against that you have got the negatives:

- Wang gone, the fall woman for the misreporting one presumes, how much was/is she the mastermind behind the company?
- Govt issues with the Mancozeb product line
- Road construction issues that the company specifically stated was not affecting production has materially affected production and will continue to do so up until March 2007 (lawyers will have a field day over this)
- Month long shut down of production facility: not enough detail as to what this is all about, as mentioned seems alot for maintenance alone
- Product supply contract for City Govt of A La Er now turns out to be a subsidy of sorts for setting up a factory in Xinjiang, as opposed to a sales order.

And of course now you have got immense credibility issues. Results can't be taken as read until you have had a chance to review the cashflow, because of the company's reliance on forward selling to peasant farmers on the back of company loans. This has always been the area which I have found most nerve racking as there is huge scope for misreporting/underprovisioning bad debt, and on the mngt's track record odds are now on for bad rather than good news on this front.

To cap it all, the company is now getting tied up in knots with litigation that seems to have a sounder base for success the more it discloses.

One would hope that this is the clean breast that would now allow us to go forward, but I suspect it is not yet all out in the open. At least statements going forward are likely to be accurate given that Amex will be watching v closely.

I now really regret not selling on the first sign of Amex issues, when there was an opportunity to get out around break-even.

However US reacting postively to todays news and I suspect with the current price there is recovery to be had, although I suspect not to recent highs of $10. I will hold to see where the recovery takes us.

[vish65] 08/1/2007 14:22

The most important point of course being that the management are just liars.(or dont have the required business acumen)

I expect Herb in the US will have another field day on this

[vish65] 08/1/2007 14:09

Update - opinions ?

seems to me like a come clean statement as they have just been digging themselves into a very big hole

Xinjiang supply contract = not a sales contract
Road construction not affected = now affecting sales
Late start on new factory.
K Wang resigns
Factory shut dowm HAS NO ONE OVER THERE HEARD OF PLANNED ROUTINE PLANT MAINTENANCE.
Insufficient plant capacity for new orders

Except a lot a repair costs etc.. to hit in the final qtr.

seems to me they have been trying to 'save face' and pulling the wool over s/holder eyes. Trouble is every time theres a new low and credability drops further. Just dont know what to believe with this lot

Dont know whether to hold or cut my huge losses

[leighbarton] 08/1/2007 12:02

Don't agree, it means that the company isn't about to be imminently delisted and is on track to get back to compliance for its listing. Should be postively recd by US I would have thought

[vish65] 08/1/2007 11:25

"Reasonable demonstration " doesnt exactly fill me confidence. I wonder if they should have kept this poorly worded statment and letter under wraps

[cimbom] 08/1/2007 08:13

RNS Number:0990P
Bodisen Biotech Inc
08 January 2007



Bodisen Biotech, Inc. ("Bodisen" or the "Company")



Bodisen Biotech Receives Preliminary Determination from Amex





Bodisen Biotech, Inc. (AMEX:BBC, London AIM:BODI, website: www.bodisen.com),
today announced that on January 4, 2007 it received a letter from the American
Stock Exchange, LLC ("Amex") indicating that the Amex has determined that the
Company has made a reasonable demonstration of its ability to regain compliance
with continued listing standards by no later than the timely filing of the
Company's Annual Report on Form 10-K for the period ended December 31, 2006 or
April 17, 2007 ("Plan Period End Date"). As stated previously, the Amex has
determined that the Company is not in compliance with certain Amex continued
listing standards. The Company's securities will continue to be listed on the
Amex during this period pursuant to an extension.



Enquiries:



Charles Stanley Securities (Nominated Adviser)

Rick Thompson / Philip Davies - 0207 149 6000







About Bodisen Biotech, Inc.

Bodisen Biotech Inc. is a leading manufacturer of liquid and organic compound
fertilizers, pesticides, insecticides and agricultural raw materials certified
by the Petroleum Chemical Industry Administrative office of China (Chemical
Petroleum Production Administrative Bureau), Shaanxi provincial government and
Chinese government. Ranked the 16th fastest growing company in China by Forbes
China in January 2006, the Company is headquartered in Shaanxi province and is a
Delaware corporation. The Company's environmentally friendly "green'" products
have been proven to improve soil and plant quality, and increase crop yields.





Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of
the 'safe harbor' provisions of the Private Securities Litigation Act of 1995.
These statements are based on the current expectations or beliefs of Bodisen
Biotech, Inc. management and are subject to risks and uncertainties that could
cause actual results to differ materially from those described in the
forward-looking statements. The potential risks and uncertainties include,
among others, the fact that this statement reflects preliminary findings, that
Bodisen's independent review and the Amex inquiry are ongoing, and that further
review may require adjustments to these statements. Please also note that there
can be no guarantee that the Company's compliance with the Amex letter dated
January 4, 2007 will guarantee its continued listing on the Amex.




This information is provided by RNS
The company news service from the London Stock Exchange
END

MSCSSSFAISWSEDF

[stegrego] 04/1/2007 13:51

If you read through some of the posts on the Yahoo board you will see that they said they couldnt or wouldnt discuss several items at the AGM -

One of those was the trade shows...

Im out of this a while back but its good for entertainment to keep an eye on it!

[leighbarton] 04/1/2007 13:46

Can't believe we have had no official info from the AGM. I would have expected some info on the 2 trade shows. I know they have to tread carefully however given they must have given out some info at the AGM that should now be made available to the wider market. V frustrating.

[gambler99] 03/1/2007 22:48

why 3 quid to buy here when in the states around $5.40c?....is this another MM ripoff?